Therapiestrategien beim Trockenen Auge – eine Übersicht über mögliche Substitutionstherapien und kausaltherapeutische Ansätze

Zusammenfassung

Die Substitutionstherapie mit Tränenersatzmitteln ist der Standard beim Trockenen Auge. Heutzutage gibt es eine unüberschaubare Vielfalt an verschiedenen Präparaten. Dieser Artikel gibt einen Überblick über altbekannte und neue Ansätze zur Substitutionstherapie (Ein-, Zwei- und Dreiphasenpräparate) sowie über Möglichkeiten zur kausalen Behandlung. Insbesondere wird hierbei auf Therapieempfehlungen in Abhängigkeit der gestörten Schicht (wässrige, muzinöse oder Lipidphase) sowie auf die immunologische Komponente eingegangen.

Abstract

Substitution therapy with artificial tears is the standard in dry eye disease. Nowadays there are a vast variety of different preparations. This article gives an overview of both new and old approaches to substitution therapy (one-, two- and three-phase preparations) as well as opportunities for the causal treatment. Here, we provide dry eye treatment options regarding sophisticated disease subgroups, classifications concerning the affected tear film layer (aqueous, mucinous or lipid phase), and immunological dysfunctions.

Schlüsselwörter

trockenes Auge - Tränenfilm - Substitutionstherapie

Key words

dry eye disease - tear film - substitution therapy

• Literatur

• 1 Herrero-Vanrell R, Peral A. [International Dry Eye Workshop (DEWS). Update of the disease]. Arch Soc Esp Oftalmol 2007; 82: 733-734
• 2 Heiligenhaus A, Koch JM, Kruse FE et al. [Diagnosis and and differentiation of dry eye disorders]. Ophthalmologe 1995; 92: 6-11
• 3 Brewitt H, Zierhut M Hrsg. Trockenes Auge: Anatomie, Physiologie, Pathophysiologie, Diagnostik, Therapie. Heidelberg: Kaden; 2001
• 4 Brewitt H. Das Trockene Auge – Diagnostik und Therapie. Augenärztliche Fortbildung 1992; 15: 11-22
• 5 Goebbels M, Spitznas M. Corneal epithelial permeability of dry eyes before and after treatment with artificial tears. Ophthalmology 1992; 99: 873-878
• 6 Kasper K, Kremling C, Geerling G. [Toxicity of a new moistening agent and preservative in vitro]. Ophthalmologe 2008; 105: 557-562
• 7 Noecker RJ, Herrygers LA. Effect of preservatives in chronic ocular therapy. Clin Surg Ophthalmol 2003; 21: 88-94
• 8 Teping C. Hyaluronsäure. Thieme Drug Report 2010; 4: 1-12
• 9 Haddox JL, Pfister RR, Yuille-Barr D. The efficacy of topical citrate after alkali injury is dependent on the period of time it is administered. Invest Ophthalmol Vis Sci 1989; 30: 1062-1068
• 10 Höh H. Hyaluronic Acid In Ophthalmology. Basel: ComMed Verlagsagentur; 2005
• 11 Marquardt R, Lemp MA Hrsg. Das Trockene Auge in Klinik und Praxis. Berlin: Springer; 1991
• 12 Brewitt H. Diagnostik und Therapie des Trockenen Auges. Teil 4: Therapie. Z prakt Augenheilkd 1996; 17: 107-114
• 13 Anonymus Monographie. Polyvinylalkohol. Bundesanzeiger; Nr. 208, 04. 11. 1993
• 14 Anonymus Monographie. Polyvidon. Bundesanzeiger; Nr. 217, 23. 11. 1991
• 15 Stoss M, Michels C, Peter E et al. Prospective cohort trial of Euphrasia single-dose eye drops in conjunctivitis. J Altern Complement Med 2000; 6: 499-508
• 16 Chiambaretta F, Pouliquen P, Menerath JM et al. [Efficacy and safety of a fluid carbomer gel versus a conventional carbomer gel in dry eye treatment]. J Fr Ophtalmol 2004; 27: 130-135
• 17 Bron AJ, Mangat H, Quinlan M et al. Polyacrylic acid gel in patients with dry eyes: a randomised comparison with polyvinyl alcohol. Eur J Ophthalmol 1998; 8: 81-89
• 18 Holly FJ, Lemp MA. Tear physiology and dry eyes. Surv Ophthalmol 1977; 22: 69-87
• 19 Debbasch C, De La Salle SB, Brignole F et al. Cytoprotective effects of hyaluronic acid and Carbomer 934P in ocular surface epithelial cells. Invest Ophthalmol Vis Sci 2002; 43: 3409-3415
• 20 Camillieri G, Bucolo C, Rossi S et al. Hyaluronan-induced stimulation of corneal wound healing is a pure pharmacological effect. J Ocul Pharmacol Ther 2004; 20: 548-553
• 21 McDonald CC, Kaye SB, Figueiredo FC et al. A randomised, crossover, multicentre study to compare the performance of 0.1 % (w/v) sodium hyaluronate with 1.4 % (w/v) polyvinyl alcohol in the alleviation of symptoms associated with dry eye syndrome. Eye (Lond) 2002; 16: 601-607
• 22 Hamano T, Horimoto K, Lee M et al. Sodium hyaluronate eyedrops enhance tear film stability. Jpn J Ophthalmol 1996; 40: 62-65
• 23 Mazzacane D, Braggio F. Randomized controlled trial of high-molecular-weight hyaluronic acid in dry eye syndromes. Ann Ottalmol Clin Ocul 1993; 119: 1-15
• 24 Perry HD. Dry eye disease: pathophysiology, classification, and diagnosis. Am J Manag Care 2008; 14: S79-S87
• 25 Ubels JL, Clousing DP, Van Haitsma TA et al. Pre-clinical investigation of the efficacy of an artificial tear solution containing hydroxypropyl-guar as a gelling agent. Curr Eye Res 2004; 28: 437-444
• 26 Wang TJ, Wang IJ, Ho JD et al. Comparison of the clinical effects of carbomer-based lipid-containing gel and hydroxypropyl-guar gel artificial tear formulations in patients with dry eye syndrome: a 4-week, prospective, open-label, randomized, parallel-group, noninferiority study. Clin Ther 2010; 32: 44-52
• 27 Gifford P, Evans BJ, Morris J. A clinical evaluation of Systane. Cont Lens Anterior Eye 2006; 29: 31-40
• 28 Rabensteiner DF, Schmut O, Wedrich A. Trockenes Auge – Alles zum Sicca-Syndrom. Wien: Verlaghaus der Ärzte; 2009
• 29 Luo L, Li DQ, Doshi A et al. Experimental dry eye stimulates production of inflammatory cytokines and MMP-9 and activates MAPK signaling pathways on the ocular surface. Invest Ophthalmol Vis Sci 2004; 45: 4293-4301
• 30 Tomlinson A, Khanal S, Ramaesh K et al. Tear film osmolarity: determination of a referent for dry eye diagnosis. Invest Ophthalmol Vis Sci 2006; 47: 4309-4315
• 31 Kaercher T, Buchholz P, Kimmich F. Treatment of patients with keratoconjunctivitis sicca with Optive: results of a multicenter, open-label observational study in Germany. Clin Ophthalmol 2009; 3: 33-39
• 32 Lallemand F, Daull P, Benita S et al. Successfully improving ocular drug delivery using the cationic nanoemulsion, Novasorb. J Drug Delivery 2012; 2012: 604204
• 33 Chen W, Zhang X, Zhang J et al. A murine model of dry eye induced by an intelligently controlled environmental system. Invest Ophthalmol Vis Sci 2008; 49: 1386-1391
• 34 Matsuo T. Trehalose protects corneal epithelial cells from death by drying. Br J Ophthalmol 2001; 85: 610-612
• 35 Strong B, Farley W, Stern ME et al. Topical cyclosporine inhibits conjunctival epithelial apoptosis in experimental murine keratoconjunctivitis sicca. Cornea 2005; 24: 80-85
• 36 Herdeiro RS, Pereira MD, Panek AD et al. Trehalose protects Saccharomyces cerevisiae from lipid peroxidation during oxidative stress. Biochim Biophys Acta 2006; 1760: 340-346
• 37 Takeuchi K, Nakazawa M, Ebina Y et al. Inhibitory effects of trehalose on fibroblast proliferation and implications for ocular surgery. Exp Eye Res 2010; 91: 567-577
• 38 Matsuo T, Tsuchida Y, Morimoto N. Trehalose eye drops in the treatment of dry eye syndrome. Ophthalmology 2002; 109: 2024-2029
• 39 Nichols KK, Foulks GN, Bron AJ et al. The international workshop on meibomian gland dysfunction: executive summary. Invest Ophthalmol Vis Sci 2011; 52: 1922-1929
• 40 Shine WE, McCulley JP. Polar lipids in human meibomian gland secretions. Curr Eye Res 2003; 26: 89-94
• 41 Bron AJ, Tiffany JM. The meibomian Glands and Tear Film Lipids. Structure, Function, and Control. In: Sullivan D, ed. Lacrimal Gland, Tear Film, and dry Eye Syndromes. New York: Plenum Press; 1998: 281-295
• 42 Dausch D, Lee S, Dausch S et al. [Comparative study of treatment of the dry eye syndrome due to disturbances of the tear film lipid layer with lipid-containing tear substitutes]. Klin Monatsbl Augenheilkd 2006; 223: 974-983
• 43 Khaireddin R, Schmidt KG. [Comparative investigation of treatments for evaporative dry eye]. Klin Monatsbl Augenheilkd 2010; 227: 128-134
• 44 Ketelson HA, Davis J, Meadows DL. Characterization of an Anionic Lipid Stabilized Ocular Emulsion Containing HP-Guar. Invest Ophthalmol Vis Sci 2010; E-Abstract 6264
• 45 Korb DR, Blackie C, Meadows D et al. Evaluation of extended tear stability by two emulsion based artifical tears. 6th International Conference on the Tear Film & Ocular Surface, Basic Science and Clnical Relevance. Florence: TFOS; 2010: 83
• 46 Foulks GN, Sindt C, Griffin J. Efficacy evaluation of a novel emulsion-based, anionic phospholipid-containing articial tear in meibomian gland dysfunction subjects. TFOS 2010. Adv Exp Med Biol 2002; 506: 1121-1125
• 47 Dinslage S, Stoffel W, Diestelhorst M et al. Tolerability and safety of two new preservative-free tear film substitutes. Cornea 2002; 21: 352-355
• 48 Goto E, Shimazaki J, Monden Y et al. Low-concentration homogenized castor oil eye drops for noninflamed obstructive meibomian gland dysfunction. Ophthalmology 2002; 109: 2030-2035
• 49 Aragona P, Spinella R, Rania L et al. Assessment of the efficacy of Cationorm® in patients with moderate dry eye compared with Optive® and Emustil® eye drops. Acta Ophthalmologica 2011; 89 (Abstracts from the 2011 European Association for Vision and Eye Research Conference Crete)
• 50 Liang H, Brignole-Baudouin F, Rabinovich-Guilatt L et al. Reduction of quaternary ammonium-induced ocular surface toxicity by emulsions: an in vivo study in rabbits. Mol Vis 2008; 14: 204-216
• 51 Zimmermann N, Erb C. Altbewährte und innovative Therapie der Volkskrankheit Blepharitis. Augenspiegel 2012; 2: 40-43
• 52 Tseng SC, Maumenee AE, Stark WJ et al. Topical retinoid treatment for various dry-eye disorders. Ophthalmology 1985; 92: 717-727
• 53 Wright P. Topical retinoic acid therapy for disorders of the outer eye. Trans Ophthalmol Soc U K 1985; 104: 869-874
• 54 Kobayashi TK, Tsubota K, Takamura E et al. Effect of retinol palmitate as a treatment for dry eye: a cytological evaluation. Ophthalmologica 1997; 211: 358-361
• 55 Goebbels M, Gross D. [Clinical study of the effectiveness of a dexpanthenol containing artificial tears solution (Siccaprotect) in treatment of dry eyes]. Klin Monatsbl Augenheilkd 1996; 209: 84-88
• 56 Schirra F, Ruprecht KW. [Dry eye. An update on epidemiology, diagnosis, therapy and new concepts]. Ophthalmologe 2004; 101: 10-18
• 57 Foulks GN, Pflugfelder SC, Lemp MA et al. A randomizied double-masked clinical trial to assess efficacy and safety of a 1 % CSA-containing ophthamlic ointment vs. placebo in patients with Keratokonjunctivits sicca (KCS) associated with Sjögrenʼs Syndrome (SS). Invest Ophthalmol Vis Sci 1996; 37: 646
• 58 Kunert KS, Tisdale AS, Gipson IK. Goblet cell numbers and epithelial proliferation in the conjunctiva of patients with dry eye syndrome treated with cyclosporine. Arch Ophthalmol 2002; 120: 330-337
• 59 Kunert KS, Tisdale AS, Stern ME et al. Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes. Arch Ophthalmol 2000; 118: 1489-1496
• 60 Schall K, Stevenson OD, Mundorf TK et al. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology 2000; 107: 631-639
• 61 Sheppard JD, Scoper SV, Samudre S. Topical loteprednol pretreatment reduces cyclosporine stinging in chronic dry eye disease. J Ocul Pharmacol Ther 2011; 27: 23-27
• 62 Brewitt H, Höh H, Kaercher T et al. Das Trockene Auge-Diagnostik und Therapie. Z prakt Augenheilkd 1997; 18: 371-379
• 63 Lemp MA. Report of the National Eye Institute/Industry workshop on Clinical Trials in Dry Eyes. CLAO J 1995; 21: 221-232
• 64 Scheuerle AF, Kruse FE. [Treatment of “dry eyes”]. Med Monatsschr Pharm 2004; 27: 199-207